Can Thymidine Phosphorylase Be a Predictive Marker for Gemcitabine and Doxifluridine Combination Chemotherapy in Cholangiocarcinoma?: Case Series

Unresectable cholangiocarcinoma is poorly responded to chemotherapy, especially for the case refractory to gemcitabine and cisplatin. Here, we tested whether high expression of thymidine phosphorylase (TP) can be a predictive biomarker for the indicator for gemcitabine and doxifluridine combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Myoung Hee, Lee, Won Sup, Go, Se-Il, Kim, Moon Jin, Lee, Un Seok, Choi, Hye Jung, Kim, Dong Chul, Lee, Jeong-Hee, Kim, Hoon-Gu, Bae, Kyung Soo, Cho, Jae Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2014
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603134/
https://www.ncbi.nlm.nih.gov/pubmed/25526478
http://dx.doi.org/10.1097/MD.0000000000000305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603134/
https://www.ncbi.nlm.nih.gov/pubmed/25526478
http://dx.doi.org/10.1097/MD.0000000000000305

Ejemplares similares